Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shorts needed to cover before the celebration can move ahead!
That calls for a sell off in lexaria land!
Let's give the left coast an hour and see how $4.50/$5 looks!
Another up day on tap, after we buy these early sellers who are happy to make a nickel and run.
Thanks
Lexaria Commences Multi-Week Human Clinical Hypertension Study
http://crweworld.com/article/news-provided-by-accesswire/2356110/lexaria-commences-multi-week-human-clinical-hypertension-study
Trading must be an algorithm to rapid for anything else
Not to worry they will probably issue a few more to themselves
Latest batch of free shares being liquidated by consultants imo
37 million plus volume wonder if history repeats itself and they get sold before close?
Nice if you haven’t been bagged reverse split on and bagged again already :p
there you go... $4.10 at 10 min in to reg trading!
Did this just get halted I swear I saw the bid at $15 for a split second before volume stopped
Only time the pps spikes on this turd is premarket when investors get no opportunity to sell
A fair statement re Bunka. He has abused his role against poor results on a compensation level IMO. Still holding on but far from impressed.
Buccal Nicotine Absorption Studies from animals to humans
Here's Chris' statements on Nicotine studies from the Letter to Shareholders from earlier this year:
"In November 2021 we issued study results that demonstrated yet another first for Lexaria: in an animal study we evidenced that DehydraTECH was effective in promoting superior nicotine drug delivery characteristics in sublingual/buccal (oral) tissue.
DehydraTECH was originally developed to promote more efficient delivery of fat-soluble drugs across the intestinal wall, so our findings demonstrating its effectiveness also in enhancing sublingual/buccal (oral) absorption greatly enhances the value proposition for our technology for the oral nicotine products sector. This nicotine study was noteworthy not just because we delivered much higher levels of nicotine, more quickly; but also because we made this breakthrough utilizing buccal tissues of the mouth, gums and throat instead of through our traditional delivery through the intestines.
This was yet another opportunity demonstrating the versatility of DehydraTECH to work effectively in different parts of the body and opens doors to drug delivery through products such as lozenges, sub-lingual tablets, and other forms of non-swallowed oral products.
Because of this important new discovery for DehydraTECH, we are launching a very similar study in humans expected to start soon. If we can demonstrate similar performance of nicotine absorption through the sublingual/buccal tissue in humans, we feel that DehydraTECH will have advanced another big step in the direction of commercial applicability".
Here's the link to the 36 person nicotine study just announced.
https://ir.lexariabioscience.com/news-events/press-releases/detail/170/lexaria-provides-update-on-human-nicotine-study-nic-h22-1
Here's the results from last year's successful animal study.
https://ir.lexariabioscience.com/news-events/press-releases/detail/153/lexaria-oral-nicotine-study-nic-a21-1-delivers-outstanding
Nobody cares right now, Bunka has destroyed his fan base. Gonna take some major news to move this again. might be out there, but thought big news was years ago
I bet you're right, but I've been wrong before! LOL
Altria must know of the nicotine study NIC-H22-1 LEXX is doing comparing their product "On" to DehydraTech. LEXX says they are paying for this study as opposed to the newly announced samples LEXX is supplying to Altria which they will receive "a fee" for. If the samples are the same ones then it would follow that LEXX and Altria have been planning this together since at least the beginning of the year when the Nicotine Study NIC-H22-1 was first announced. Either way, these collaborations are very positive considering we've done business with Altria before. We obviously haven't burned our proverbial bridges just yet!
It definitely seems the move to the buccal absorption format is picking up steam. The results from the Nicotine test results last Oct and now a new patent for buccal absorption (so far in Australia only but US and EU coming soon) are huge signs this is the direction our nicotine tech is going.
"As reported on October 5, 2021, Lexaria demonstrated in animal study NIC-A21-1 that nicotine oral pouches using DehydraTECH technology were 10x to 20x faster in reaching peak delivery of nicotine to bloodstream than controls. Findings using a DehydraTECH nicotine benzoate formulation relative to a concentration-matched control from that study are shown in the figure above.
The oral nicotine pouch category is of intense interest to Lexaria and is one of the fastest growing segments of the nicotine industry due in part to its reduced risk health outcomes as noted by the Food and Drug Administration ("FDA"). This delivery method, in the white pouch format specifically, which avoids harmful lung outcomes experienced by smokers or vapers, involves absorption primarily through the buccal tissues of the mouth, of purified nicotine that has been separated from most other harmful compounds in the tobacco leaf. The global market for the oral nicotine pouch category was US$2.33 billion in 2020 and is growing at a rapid CAGR of 30.7% and is expected to reach $21.84 billion in 2027.
As reported on March 8, 2022, Lexaria recently received its first ever patent granted to use DehydraTECH to more efficiently deliver nicotine through buccal tissue absorption. Similar patent filings have been made in the USA and in the EU and Lexaria believes those potential patent awards could support significant competitive advantages in the nicotine white pouch category, as well as other oral nicotine product formats.
"...test articles are currently being manufactured." You have to wonder if theses are the same compounds that Altria is paying Lexaria to manufacture.
I would hazard a guess and say that Lexaria has given up on fully orally ingestable nicotine products and is now concentrating on proving the viability of a product that can be absorbed through the buccal tissues. It's unclear whether the compounds that are being readied for Altria are of this type.
This is awesome news. It's too bad Bunka can't share more info re: this agreement but when companies are creating new products which are highly competitive, the company owning the product not the one with the licensed tech, has first rights to the announcement of said new products with tech included.
Can't wait for LEXX to get its first paying nicotine and/or pharma licensing deals. Time for the SP to move on out.
It appears so, at least partially. Looking forward to being completely wrong. LOL
You're wrong now lol.
I agree AgentSmith - figuring the same myself.
Seems like big news -- thought the pps would jump up a little more... I will hang in there GLTA
Almost regardless of context, when a company like Altria "nibbles", then disappears, then comes back, I'd figure that's a pretty darned good sign...!
('Course I've done plenty of "figuring" that's been just plain wrong; so, use your own judgment. *XD)
@harlem Is that big news? Seems like it would be . . ..
The connection we need!!!
ALTRIA NEWS - Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
Kelowna, British Columbia, April 11, 2022 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC (“Altria”).
Under the terms of these agreements, Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to be evaluated by Altria. The new agreements are in effect until March 31, 2023.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
No one needs to be here. If you have criticism or accolades for Lexaria, just send them an email.
There's a constant flux of new investor's. i.e. According to this list of Lexaria's Institutional Holdings, Invenomic Capital management currently owns 359,113 shares.
https://www.nasdaq.com/market-activity/stocks/lexx/institutional-holdings
I imagine that as the hopefully good news on FDA phases 1 and 2 are announced for the CBD indications for NDI's that the new institutional investors action should heat up. I would have liked to see things happen faster just like anyone but the groups with the big bucks are the ones controlling the SP and obviously the move to Big Pharma is a longer road than making puny royalty deals with Mom and Pop shops.
As far as a company partnering up with Lexaria, this would be the worst time for that with the SP at ATL. Better to give a partner 10% of the company at 100M cap than 50% of the company at 20M cap.
Definitely feeling positive for the coming year.
@ Abundance You want to hide behind legalities? I don't think anyone's saying he did anything illegal. In January 2020 he was quoted as saying that a big part of his plan was to uplist, and bring in a bunch of new investors. "A key facet of that plan is to list on a major US stock exchange, opening up the company to a new pool of investors, Bunka told shareholders." https://www.proactiveinvestors.com/companies/news/910312/lexaria-bioscience-planning-to-list-on-a-major-us-exchange-in-2020-says-ceo-910312.html
Except, that hasn't happened, as far as I can tell. You say it wasn't a promise. Okay, but where's the explanation for why it hasn't happened? The uplisting was supposed to make a difference. It hasn't. I don't blame people for being disappointed.
Yes, this used to be an extremely active board. Now, press releases, and cheerleaders Abundance and Ted O are not enough to keep people here.
It boils down to you believe Bunka and I am not at all confident in what he says... but I do wish him MUCH success as my money in on the table. His success is my success. I have disagreed with family and friends over the years but wish them and you as well the best. Its not a question of negative - its a question of disappointment with the results to date....nicotine - nothing to date (but I hope he does make a $billion deal) , Nas listing successful?, pps over past two years, Bunka taking $356k salary- two percent of the sale of a division and stock options seems a bit much for the results at the moment. And I wish you well and to see you extremely successful with Lexy - selfishly I win too.
What does me being happy have to do with your false info?
Are you every big investor's spokesperson?
You say you're hopeful and wish me luck but I take that as I do with all forward leading comments on bull boards, maybe true, maybe not true. I'm leaning toward the latter.
I guess you are happy with the results/success for the past few years...the market/big investors and apparently most investors are not impressed. I hope Bunka pulls off a miracle but to date the pps/the market is saying Bunka you are not earning your $356k salary etc. gltu stay well
The onus is on the buyer, not the Bunka! Bunka has never promised anything because he knows better. Insiders can only legally say what they think may or may not come true. Investors and traders need to read between the lines and listen more carefully to exactly what is said. Also, read the disclaimers titled "Caution regarding forward looking statements" on all the news releases and on any news release for any publicly owned company for that matter.
Here's one from one of the latest Lexaria news releases:
"This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law".
Abundance please tell whats not true and I will stand corrected and happier for it. ty
Harlem - Your comments are all negative, completely out of context and mostly untrue. For someone who hopes for the best outcome in the stock, you sure have a funny way of inspiring new investors. Perhaps some comments re: all the great studies being done and extremely positive future we have. To help you out I have posted a link to Lexaria's News Release history. Things are actually a lot better than you portend. https://ir.lexariabioscience.com/news-events/press-releases
TACO - Bunka has said, several years ago, that he would put six deals or more on the table, Chrgd is great, money would pour in after the listing on NAS as the big boys could invest, Altria is going great, BAT is great, lots of companies at the door - PPS in past two years in the toilet, cash for another year at best. IF there is an interest in developing a product it will in all probability be for something specific and not include day to day operations/expenses such as the $600k plus yearly salary of Bunka and Dr John they suck out of this small company. Holding shares for a long time and not sold any...REALLY want to see it succeed but also concerned about another raise in the not too distant future. Last year Bunka said "the PPS should be a 100x multiple" of what it is - I agree - unfortunately I am very disappointed in the guidance he has given in the past few years and the results to date. Holding my shares to the bitter end or magical finish. Wishing everyone the best.
For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study.
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka.
These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses.
Do you get corn the day, week, or month after it is planted? It's called investing, not day trading. If you are a serious investor, you would know the big money, long term, is intellectual property(patents). If you did any DD at all you would know they now have at least 23 patents. Also, Mr Bunka has major skin in the game, 3rd most shares held in the company and over 12% ownership by insiders which is not too shabby.
DehydraTECH making news.New Hill Street deal in the States. https://ceo.ca/@newsfile/hill-street-announces-major-new-us-dehydratechtm
Ted Ohashi-Page 9
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_5aceab90777d4af28a0f0f7e5fdf2d0f.pdf
Question of the Week
“I received a lot of positive feedback following my interview with Chris Bunka, Chief Executive Officer
of Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) last week however, the one issue several people questioned was the delay in receiving results from the Hypertension #3 study.
The questions I received about Hypertension #3 covered a wide range of issues including:
1. It is hard to believe the results have been in for over three months and haven’t been analysed.
2. If there was good news, it would have been reported right away.
3. Bad news is always late.
4. How can you start Hypertension #4 when #3 hasn’t been completed?
9
Let me start out by saying I have known and followed Chris Bunka for six years now and he has never
once lied to me. I’m not saying all of his expectations have come to fruition exactly as anticipated but
in business, not everything works out as you expect. This is a totally normal characteristic of operating
a company. I believe Bunka is a person of high integrity and character.
I asked Lexaria Bioscience (CSE: LXX) (NASDAQ: LEXX) (NASDAQ: LEXXW) Chief Executive Officer Chris Bunka about your concerns. Here are his responses.
• Without equivocation, we simply do not have the results yet. No fudging.
No hedging. We do not have the results. We engaged two additional PhDs ourselves and there are another six that were added through our regulatory consulting firm. We are struggling to keep up with the all the compliance and data assessment.
• To give you some idea of what is involved in one of these larger studies,
our upcoming human nicotine study will produce approximately 1,200 vials of blood. Each of
those vials will be analysed for around a dozen different variables. Each sample also has to be
properly processed, labelled and stored. That's around 14,000 pieces of data that need to be
reviewed. It simply takes a long time to complete.
• We have had a very active testing program going on in 2021 to 2023 but we do have limited
resources. As a result, we have to prioritize our activities and are staying focussed on what we
believe are the most important priorities for achieving commercialization. We believe getting
Hyper H21 4 launched on time is far more important than data analysis from Hyper H21 3. The
Hypertension #3 analysis is important but not as important from a commercial point of view.
• Please impress upon your readers that we have a lot of work to do and we are going as fast as
week can. Anyone who thinks there is something else afoot is mistaken.
Conclusion: as closely as investors might follow a company, it is never the same as being there day
by day. I believe Bunka has provided a clear and concise answer to the question. As I have said many
times in the past
few quarters, I believe LEXX has a
major opportunity
in hypertension.
That is why management has decided to carry
their work in hypertension further along into the FDA approval process. If they are successful, the
results for shareholders will be remarkable, in my opinion. I have consistently had Lexaria Bioscience
(NASDAQ: LEXX) (NASDAQ: LEXXW) as one of my favourites. Perhaps this gives readers some
further input into why I rate them so highly.
Followers
|
220
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
34627
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |